Jointly Owned Sample Clauses
The "Jointly Owned" clause defines the terms under which two or more parties share ownership rights in a particular asset, such as intellectual property, real estate, or equipment. It typically outlines each party's rights and responsibilities regarding the use, management, and potential transfer or licensing of the jointly owned asset. For example, the clause may specify how decisions are made about the asset, how profits or expenses are divided, and what happens if one party wishes to sell their share. The core function of this clause is to prevent disputes by clearly establishing the rules for shared ownership and ensuring all parties understand their entitlements and obligations.
POPULAR SAMPLE Copied 1 times
Jointly Owned. All other inventions developed by the Parties or by either Party under this Agreement or the Clinical Supply Agreement shall be the joint property of the Parties (“Joint IP”), provided that it does not belong under Section 7.1(a) or (b) to either LTS IP or NeurogesX IP. Neither Party shall have any obligation to account to the other Party for profits with respect to, or to obtain any approval of the other Party to license or exploit, any Joint IP by reason of their joint ownership, and each Party waives any such right it might have under the applicable laws in any country; provided, that NeurogesX shall only have the right to exploit and license the Joint IP for VR1-Ligand applications and products, and LTS shall only have the right to exploit or license the Joint IP for any applications and products other than VR1-Ligand applications and products.
Jointly Owned. In the event of any invention jointly owned by the parties under Section 4.1 above, ABX shall have the sole right and responsibility (but not the obligation), at its expense, to file, prosecute and maintain all patent applications (and to conduct any interferences, oppositions, or reexaminations thereon, and to request any reissues or patent term extensions thereof) claiming any XenoMouse Animals or any uses thereof, and GNE shall have the sole right and responsibility (but not the obligation), at its expense, to file, prosecute and maintain all patent applications and patents (and to conduct any interferences, oppositions, or reexaminations thereon, and to request any reissues or patent term extensions thereof) claiming the Product Antigen, any Antibody or Product and/or its development, manufacture, use or sale. The party having such rights and responsibilities hereunder is referred to as the "Controlling Party". The Controlling Party shall: (i) provide the non-Controlling Party with any patent application filed hereunder by the Controlling Party promptly after such filing; (ii) provide the non-Controlling Party promptly with copies of all substantive communications received from or filed in patent office(s) with respect to such filings; (iii) notify the non-Controlling Party of any interference, opposition, reexamination request, nullity proceeding, appeal or other interparty action and review it with the non-Controlling Party as reasonably requested; and (iv) provide the non-Controlling Party, a reasonable time prior to taking or failing to take any action that would substantially affect the scope of validity of rights under such patent applications or patents thereon (including substantially narrowing or canceling any claim without reserving the right to file a continuing or divisional application, abandoning any patent or not filing or perfecting the filing of any patent application) with notice of such proposed action so that the non-Controlling Party has a reasonable opportunity to review and make comments. If the Controlling Party fails to undertake the filing of a patent application (or continuing or divisional application) within ninety (90) days after a written request from the non-Controlling Party to do so, or if the Controlling Party discontinues the prosecution or maintenance of a patent application or patent, the non-Controlling Party at its expense may, in its discretion, undertake such filing, prosecution or maintenance thereof, in which...
Jointly Owned. (1) If the R&D Project is jointly funded by the parties and either: (1) OpNext Japan contributes fifty percent (50%) or more of the New Development Costs to the R&D Project; or (2) OpNext Japan contributes less than fifty percent (50%) of the New Development Costs to the R&D Project but the parties determine through good faith negotiations that OpNext Japan contributed to the R&D Project in some other fashion, and in both (1) and (2) above the resulting Intellectual Property can clearly be identified with reasonable certainty as that resulting from such R&D Project, then such Intellectual Property shall be deemed Jointly Developed Intellectual Property and shall be owned jointly by the parties and either party may practice such Jointly Developed Intellectual Property without an accounting or compensation to, or the consent of, the other party. Except as set forth in Section 4(c)(iii) below, if either party desires to license any of its rights to the Jointly Developed Intellectual Property herein to a third party, it shall obtain the prior written consent of the other party hereto. Each party shall have the right to apply, in both parties’ names, for Intellectual Property protection in the Jointly Developed Intellectual Property. The parties shall agree on the proper way and strategy for proceeding with all protection of the Jointly Developed Intellectual Property in accordance with the R&D Procedures. All expenses incurred in obtaining and maintaining Intellectual Property protection in the Jointly Developed Intellectual Property shall be equally shared by the parties. In the event that one (1) of the parties elects not to seek or maintain patent or other intellectual or industrial property protection for any Jointly Developed Intellectual Property in any particular country or not to share equally in the expenses thereof with the other party, the other party shall have the right to seek or maintain such protection at its sole expense in such country and shall have full control over the prosecution and maintenance thereof even though title to any patent or other intellectual or industrial property protection issuing therefrom shall be jointly owned by the parties.
(2) To the extent OpNext Japan shares the costs of its proportion of the joint funding as described in (1) above, with either OpNext R&D-USA or any other Wholly-Owned Subsidiary of OpNext, Inc. for an R&D Project that is jointly funded by Hitachi and OpNext Japan, OpNext Japan shall have the right...
Jointly Owned. WAGONS In the case of jointly owned wagons, extant free time & demurrage rules as applicable for detention of railway owned stock by normal rail users (i.e. other than steel plants) will be applicable. However, demurrage charge will be levied @ 50% of the rate of demurrage charge as applicable to normal Rail users (i.e. other than steel plants).
Jointly Owned. (a) JTI shall have the first right and responsibility (but not the obligation), at its expense, to file, prosecute and maintain all patent applications and patents (and to conduct any interferences, oppositions, or reexaminations thereon, and to request any reissues or patent term extensions thereof) claiming any invention that is jointly-owned by the Parties in accordance with Section 6.5 (a "Joint Invention") and/or its development, manufacture, use or sale.
(b) In connection with the activities of JTI described in Section 6.7.2, JTI shall: (i) provide to ABX any patent application filed by JTI that covers a Joint Invention promptly after such filing; (ii) provide ABX promptly with copies of all substantive communications received from or filed in patent office(s) with respect to such filings; (iii) notify ABX of any interference, opposition, reexamination request, nullity proceeding, appeal or other inter-party action and review such action with ABX as reasonably requested; and (iv) notify ABX if JTI intends to take or refrain from taking any action that would substantially [*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
11. affect the scope or validity of, or rights under, such patent applications or patents thereon (including substantially narrowing or canceling any claim without reserving the right to file a continuing or divisional application, abandoning any patent or not filing or perfecting the filing of any patent application) reasonably advance of any deadlines relating thereto so that ABX has a reasonable opportunity to review and make comments thereon.
Jointly Owned. The name of the Joint Library and the Library Building and any ancillary names thereto together with the image of the Library Building and any logos created for the Joint Library shall be jointly owned by the University and the City.
Jointly Owned. All technology developed and funded jointly by the Parties for use in the Joint Library shall be jointly owned by the University and the City.
Jointly Owned. Unless and to the extent either Paragraph 16.3.1 or a separate written agreement between 3M and IMATION provides otherwise, including, but not limited to, any agreement pursuant to Paragraph 14.1 or 14.2, 3M and IMATION shall jointly own all right, title and interest to Joint Foreground PI, Joint Foreground Patents and any other intellectual property, whether patented or not, conceived jointly by one or more employees, agents or contract employees of 3M and one or more employees, agents or contract employees of IMATION, with each Party having an undivided, fifty (50) percent interest therein.
9. LICENSE GRANT TO IMATION UNDER 3M FOREGROUND PI, 3M FOREGROUND PATENTS, JOINT FOREGROUND PI AND JOINT FOREGROUND PATENTS
9.1. 3M hereby grants to IMATION paid-up, royalty-free, worldwide licenses, including the right to manufacture, have manufactured (subject to Paragraph 15.3), use, offer to sell, sell and import, as follows:
9.1.1. a non-exclusive license, with a right to sublicense IMATION Affiliates, and third parties to the extent permitted by Article 11, under the 3M Foreground PI and 3M Foreground Patents in the Non-Exclusive Fields and IMATION Supply Fields; and
9.1.2. an exclusive license (subject to any licenses granted by 3M prior to the Distribution Date to third parties which are not 3M Affiliates), with a right to sublicense IMATION Affiliates, and third parties to the extent permitted by Article 11, under the 3M Foreground PI and 3M Foreground Patents, and under 3M's interest in the Joint Foreground PI and Joint Foreground Patents in the IMATION Exclusive Fields.
10. LICENSE GRANT TO 3M UNDER IMATION FOREGROUND PI, IMATION FOREGROUND PATENTS, JOINT FOREGROUND PI AND JOINT FOREGROUND PATENTS
10.1. IMATION hereby grants to 3M paid-up, royalty-free, worldwide, irrevocable licenses, including the right to manufacture, have manufactured (subject to Paragraph 15.3), use, offer to sell, sell and import, as follows:
10.1.1. a non-exclusive license, with a right to sublicense 3M Affiliates, and third parties to the extent permitted by Article 11, under the IMATION Foreground PI and IMATION Foreground Patents in the Non-Exclusive Fields and 3M Supply Fields; and
10.1.2. an exclusive license, with the right to sublicense 3M Affiliates, and third parties to the extent permitted by Article 11, under IMATION Foreground PI and IMATION Foreground Patents and under IMATION's interest in Joint Foreground PI and Joint Foreground Patents in the 3M Business Fields, but n...
Jointly Owned. All other Inventions shall be the joint property of the Parties (“Joint Inventions”). Either Party shall have the right to license Joint Inventions to a third party, provided, however, for so long as LTS is Manufacturing the Drug Product on behalf of NuPathe, (i) LTS may not grant any license to a Joint Invention to any third party for use in connection with the manufacture, sale, marketing, importation or distribution of any iontophoretic TTS containing sumatriptan; and (ii) except in connection the exercise of its Back-up Rights pursuant to Section 2.8 of this Agreement, NuPathe may not grant any license to such Joint Invention to any third party for use in connection with the manufacture of any iontophoretic TTS containing the sumatriptan.
Jointly Owned. Subject to the restrictions in this Section, the ------------- Converted User Data shall be deemed to be the property of both of the parties and each party shall be free to license or otherwise exploit such information with no duty of accounting to the other party. All other data collected by Snowball or ▇▇▇.▇▇▇ shall be deemed to be the property of the collecting party. Both parties acknowledge that any data concerning Converted Users that a party has gathered independent of this Agreement shall not be covered by this Agreement. ▇▇▇.▇▇▇ acknowledges that the User Data that is not part of the Converted User Data is the sole and exclusive property of Snowball.